^
    Back
    Association details:
    Biomarker:KIT exon 9 mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/13/2023
    Excerpt:
    CONTRADICTING EVIDENCE:...Gastrointestinal Stromal Tumor….Treatment for Progressive Disease….Dose escalation of imatinib as tolerated (if previously treated with standard-dose imatinib; may be most effective for patients with KIT exon 9 mutation)
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

    Excerpt:
    ...- Primary mutation at KIT exon 9...
    Trial ID:
    NCT01541709
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

    Excerpt:
    ...- Gene mutation test report including c-kit exons 9,11,13 and 17 and platelet-derived growth factor receptor alpha (PDGFRA) exons 12 and 18...
    Trial ID:
    ZJGIST-01
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Adjuvant imatinib in GIST patients harboring exon 9 KIT mutations: results from a multi-institutional European retrospective study

    Published date:
    10/06/2021
    Excerpt:
    In the weighted multivariate Cox models, high-dose imatinib was not associated to the survival outcomes (RFS: HR 1.24, 95% CI 0.79-1.94; mRFS: HR 1.69, 95% CI 0.92-3.10; IFFS: HR 1.35, 95% CI 0.79-2.28)….In this retrospective series of KIT exon 9-mutated GIST patients treated with adjuvant imatinib, a daily dose of 800 mg versus 400 mg did not show better results in terms of survival outcomes.
    DOI:
    10.1158/1078-0432.CCR-21-1665
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Eur J Surg Oncol
    Title:

    The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice

    Published date:
    08/16/2020
    Excerpt:
    The majority of GIST cases harboured exon 11 KIT mutations (88 cases, 82%), 11 cases had exon 9 KIT mutations (10%), 8 had other KIT/PDGFRA mutations potentially sensitive to imatinib. The disease relapse was detected in 19 patients, of them in 5 cases in exon 9 KIT mutants (45%), and 14 cases in patients with exon 11 KIT mutations (11%) [p < 0.01].
    DOI:
    10.1016/j.ejso.2020.08.004